NASDAQ:GLYC - GlycoMimetics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$17.72 +0.03 (+0.17 %)
(As of 05/22/2018 04:00 PM ET)
Previous Close$17.69
Today's Range$17.19 - $18.20
52-Week Range$10.06 - $26.05
Volume345,300 shs
Average Volume729,963 shs
Market Capitalization$782.37 million
P/E Ratio-15.70
Dividend YieldN/A
Beta3.43

About GlycoMimetics (NASDAQ:GLYC)

GlycoMimetics logoGlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. Its advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and has evaluated in a Phase 3 clinical trial, conducted by its strategic collaboration with Pfizer Inc. The company's drug candidate, GMI-1271, an E-selectin antagonist, is evaluated in a Phase 1/2 clinical trial as a potential treatment for acute myeloid leukemia and is in a Phase 1 clinical trial for the treatment of multiple myeloma. It is also developing a Phase 1 clinical trial drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Receive GLYC News and Ratings via Email

Sign-up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GLYC
CUSIPN/A
Phone240-243-1201

Debt

Debt-to-Equity RatioN/A
Current Ratio28.32
Quick Ratio28.32

Price-To-Earnings

Trailing P/E Ratio-15.70
Forward P/E Ratio-15.15
P/E GrowthN/A

Sales & Book Value

Annual Sales$20,000.00
Price / Sales37,655.00
Cash FlowN/A
Price / CashN/A
Book Value$3.49 per share
Price / Book5.08

Profitability

EPS (Most Recent Fiscal Year)($1.13)
Net Income$-33,280,000.00
Net MarginsN/A
Return on Equity-25.35%
Return on Assets-24.04%

Miscellaneous

Employees40
Outstanding Shares42,500,000

GlycoMimetics (NASDAQ:GLYC) Frequently Asked Questions

What is GlycoMimetics' stock symbol?

GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."

How were GlycoMimetics' earnings last quarter?

GlycoMimetics Inc (NASDAQ:GLYC) released its earnings results on Thursday, May, 3rd. The biotechnology company reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by $0.05. View GlycoMimetics' Earnings History.

What price target have analysts set for GLYC?

5 brokers have issued 1-year price targets for GlycoMimetics' stock. Their forecasts range from $21.00 to $35.00. On average, they expect GlycoMimetics' stock price to reach $28.25 in the next year. View Analyst Ratings for GlycoMimetics.

Who are some of GlycoMimetics' key competitors?

Who are GlycoMimetics' key executives?

GlycoMimetics' management team includes the folowing people:
  • Mrs. Rachel K. King, CEO & Director (Age 59)
  • Mr. Brian M. Hahn, CFO & Sec. (Age 44)
  • Dr. John L. Magnani Ph.D., Sr. VP of Research, Chief Scientific Officer & Director (Age 65)
  • Dr. Helen M. Thackray M.D., FAAP, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 50)
  • Mr. Henry Flanner, VP of Technical Operations

Has GlycoMimetics been receiving favorable news coverage?

Media coverage about GLYC stock has been trending somewhat positive on Tuesday, according to Accern. The research firm identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. GlycoMimetics earned a daily sentiment score of 0.13 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 46.69 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are GlycoMimetics' major shareholders?

GlycoMimetics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include OppenheimerFunds Inc. (5.89%), Redmile Group LLC (5.37%), Franklin Resources Inc. (4.96%), BlackRock Inc. (2.79%), Columbus Circle Investors (1.32%) and Artal Group S.A. (0.76%). Company insiders that own GlycoMimetics stock include Daniel M Junius, Helen M Thackray and M James Barrett. View Institutional Ownership Trends for GlycoMimetics.

Which institutional investors are selling GlycoMimetics stock?

GLYC stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD. and Barclays PLC. Company insiders that have sold GlycoMimetics company stock in the last year include Helen M Thackray and M James Barrett. View Insider Buying and Selling for GlycoMimetics.

Which institutional investors are buying GlycoMimetics stock?

GLYC stock was acquired by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Redmile Group LLC, Columbus Circle Investors, Farallon Capital Management LLC, Millennium Management LLC, BlackRock Inc., Franklin Resources Inc. and Point72 Asset Management L.P.. View Insider Buying and Selling for GlycoMimetics.

How do I buy shares of GlycoMimetics?

Shares of GLYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GlycoMimetics' stock price today?

One share of GLYC stock can currently be purchased for approximately $17.72.

How big of a company is GlycoMimetics?

GlycoMimetics has a market capitalization of $782.37 million and generates $20,000.00 in revenue each year. The biotechnology company earns $-33,280,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis. GlycoMimetics employs 40 workers across the globe.

How can I contact GlycoMimetics?

GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-243-1201 or via email at [email protected]


MarketBeat Community Rating for GlycoMimetics (GLYC)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  181 (Vote Outperform)
Underperform Votes:  126 (Vote Underperform)
Total Votes:  307
MarketBeat's community ratings are surveys of what our community members think about GlycoMimetics and other stocks. Vote "Outperform" if you believe GLYC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLYC will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

GlycoMimetics (NASDAQ:GLYC) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for GlycoMimetics in the last 12 months. Their average twelve-month price target is $28.25, suggesting that the stock has a possible upside of 59.42%. The high price target for GLYC is $35.00 and the low price target for GLYC is $21.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $28.25$25.00$24.60$18.20
Price Target Upside: 59.42% upside37.14% upside13.16% upside73.17% upside

GlycoMimetics (NASDAQ:GLYC) Consensus Price Target History

Price Target History for GlycoMimetics (NASDAQ:GLYC)

GlycoMimetics (NASDAQ:GLYC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/7/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$23.00 ➝ $25.00MediumView Rating Details
2/8/2018Roth CapitalSet Price TargetBuy$35.00MediumView Rating Details
12/20/2017Jefferies GroupReiterated RatingBuy$21.00MediumView Rating Details
12/12/2017SunTrust BanksBoost Price TargetBuy$32.00HighView Rating Details
12/6/2017CowenReiterated RatingBuyLowView Rating Details
5/19/2017Canaccord GenuityReiterated RatingBuy$12.00HighView Rating Details
(Data available from 5/22/2016 forward)

Earnings

GlycoMimetics (NASDAQ:GLYC) Earnings History and Estimates Chart

Earnings by Quarter for GlycoMimetics (NASDAQ:GLYC)

GlycoMimetics (NASDAQ:GLYC) Earnings Estimates

2018 EPS Consensus Estimate: ($0.54)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.29)($0.27)($0.28)
Q2 20182($0.29)($0.27)($0.28)
Q3 20182($0.33)($0.27)($0.30)
Q4 20182($0.38)$1.03$0.33

GlycoMimetics (NASDAQ GLYC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2018Q1 2018($0.28)($0.33)ViewN/AView Earnings Details
3/6/2018Q4 2017($0.2560)($0.27)ViewListenView Earnings Details
11/8/2017Q3 2017($0.2840)($0.24)ViewN/AView Earnings Details
8/3/2017Q2 2017($0.3670)($0.30)ViewN/AView Earnings Details
5/8/2017Q1 2017($0.3680)($0.34)ViewN/AView Earnings Details
3/1/2017Q4 2016($0.35)($0.36)$4.50 millionViewN/AView Earnings Details
11/4/2016Q216($0.44)($0.34)$0.02 millionViewN/AView Earnings Details
8/4/2016Q2 2016($0.44)($0.41)ViewN/AView Earnings Details
5/4/2016Q116($0.47)($0.40)ViewN/AView Earnings Details
2/29/2016Q4($0.38)($0.47)$35.00 millionViewN/AView Earnings Details
11/12/2015Q3($0.40)($0.38)$2.10 millionViewN/AView Earnings Details
8/6/2015Q2 2015($0.40)$0.51$20.04 millionViewN/AView Earnings Details
5/5/2015Q1 2015($0.38)($0.37)ViewN/AView Earnings Details
3/16/2015Q4 2014($0.22)($0.39)ViewN/AView Earnings Details
10/31/2014Q314$0.21($0.35)$10.00 millionViewN/AView Earnings Details
7/31/2014Q2 2014$0.24$0.39$9.08 million$15.03 millionViewN/AView Earnings Details
5/8/2014Q114($0.28)($0.30)ViewN/AView Earnings Details
3/31/2014($2.17)($2.80)$9.65 million$0.08 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

GlycoMimetics (NASDAQ:GLYC) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

GlycoMimetics (NASDAQ GLYC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 26.10%
Insider Trading History for GlycoMimetics (NASDAQ:GLYC)
Institutional Ownership by Quarter for GlycoMimetics (NASDAQ:GLYC)

GlycoMimetics (NASDAQ GLYC) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/10/2018M James BarrettDirectorSell9,539$17.81$169,889.59View SEC Filing  
12/8/2017Helen M ThackraySVPSell2,000$15.01$30,020.00148,615View SEC Filing  
9/18/2017Helen M ThackraySVPSell2,000$13.00$26,000.00150,615View SEC Filing  
5/25/2017Helen M ThackraySVPSell2,000$15.57$31,140.00152,615View SEC Filing  
5/19/2017Helen M ThackraySVPSell2,000$12.14$24,280.00154,615View SEC Filing  
12/20/2016Daniel M. JuniusDirectorBuy5,000$6.01$30,050.00View SEC Filing  
10/3/2016Helen M ThackrayVPSell4,000$7.00$28,000.00156,715View SEC Filing  
7/20/2016Helen M ThackrayVPSell2,000$8.00$16,000.00160,615View SEC Filing  
7/6/2016Helen M ThackrayCMOSell22,000$7.00$154,000.00179,547View SEC Filing  
3/4/2016Mark Alan GoldbergDirectorBuy10,397$4.77$49,593.6911,497View SEC Filing  
12/22/2014Michael A HenosDirectorSell21,257$8.52$181,109.64View SEC Filing  
12/17/2014Michael A HenosDirectorSell6,725$8.97$60,323.25View SEC Filing  
12/15/2014Michael A HenosDirectorSell1,604$8.98$14,403.92View SEC Filing  
6/13/2014Michael A HenosDirectorBuy11,000$6.39$70,290.00View SEC Filing  
1/15/2014Enterprise Associates 13 L NewMajor ShareholderBuy512,500$8.00$4,100,000.00View SEC Filing  
1/15/2014M James BarrettDirectorBuy1,000,000$8.00$8,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

GlycoMimetics (NASDAQ GLYC) News Headlines

Source:
DateHeadline
New Research Coverage Highlights Apollo Commercial Real Estate Finance, Drive Shack, GlycoMimetics, Dycom ...New Research Coverage Highlights Apollo Commercial Real Estate Finance, Drive Shack, GlycoMimetics, Dycom ...
globenewswire.com - May 22 at 8:42 AM
-$0.33 EPS Expected for GlycoMimetics (GLYC) This Quarter-$0.33 EPS Expected for GlycoMimetics (GLYC) This Quarter
www.americanbankingnews.com - May 16 at 1:05 PM
GlycoMimetics (GLYC) Director Sells $169,889.59 in StockGlycoMimetics (GLYC) Director Sells $169,889.59 in Stock
www.americanbankingnews.com - May 11 at 8:23 PM
BidaskClub Upgrades GlycoMimetics (GLYC) to "Buy"BidaskClub Upgrades GlycoMimetics (GLYC) to "Buy"
www.americanbankingnews.com - May 9 at 6:39 PM
GlycoMimetics (GLYC) Receives Average Recommendation of "Buy" from BrokeragesGlycoMimetics (GLYC) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 7 at 7:24 PM
GlycoMimetics (GLYC) to Post Q4 2018 Earnings of $1.03 Per Share, Jefferies Group ForecastsGlycoMimetics (GLYC) to Post Q4 2018 Earnings of $1.03 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - May 7 at 4:20 AM
GlycoMimetics (GLYC) CEO Rachel King on Q1 2018 Results - Earnings Call TranscriptGlycoMimetics' (GLYC) CEO Rachel King on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 6 at 7:01 PM
GlycoMimetics (GLYC) Posts Quarterly  Earnings Results, Misses Estimates By $0.05 EPSGlycoMimetics (GLYC) Posts Quarterly Earnings Results, Misses Estimates By $0.05 EPS
www.americanbankingnews.com - May 4 at 7:52 PM
Edited Transcript of GLYC earnings conference call or presentation 3-May-18 12:30pm GMTEdited Transcript of GLYC earnings conference call or presentation 3-May-18 12:30pm GMT
finance.yahoo.com - May 4 at 8:45 AM
ValuEngine Upgrades GlycoMimetics (GLYC) to Strong-BuyValuEngine Upgrades GlycoMimetics (GLYC) to Strong-Buy
www.americanbankingnews.com - May 3 at 5:12 PM
GlycoMimetics: 1Q Earnings SnapshotGlycoMimetics: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 4:59 PM
Earnings Reaction History: GLYCOMIMETICS, 100.0% Follow-Through Indicator, 13.9% SensitiveEarnings Reaction History: GLYCOMIMETICS, 100.0% Follow-Through Indicator, 13.9% Sensitive
www.nasdaq.com - May 3 at 8:43 AM
BRIEF-Glycomimetics Reports Qtrly Loss Per Share Of $0.33BRIEF-Glycomimetics Reports Qtrly Loss Per Share Of $0.33
www.reuters.com - May 3 at 8:43 AM
GlycoMimetics Reports First Quarter 2018 ResultsGlycoMimetics Reports First Quarter 2018 Results
finance.yahoo.com - May 3 at 8:43 AM
-$0.28 EPS Expected for GlycoMimetics (GLYC) This Quarter-$0.28 EPS Expected for GlycoMimetics (GLYC) This Quarter
www.americanbankingnews.com - April 28 at 11:12 PM
GlycoMimetics to Report First Quarter 2018 Financial Results on May 3, 2018GlycoMimetics to Report First Quarter 2018 Financial Results on May 3, 2018
finance.yahoo.com - April 26 at 4:57 PM
GlycoMimetics (GLYC) Given a $21.00 Price Target at SunTrust BanksGlycoMimetics (GLYC) Given a $21.00 Price Target at SunTrust Banks
www.americanbankingnews.com - April 12 at 11:52 PM
GlycoMimetics Inc (GLYC) Receives Consensus Recommendation of "Buy" from AnalystsGlycoMimetics Inc (GLYC) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 12 at 7:41 PM
 Brokerages Anticipate GlycoMimetics Inc (GLYC) to Post -$0.28 EPS Brokerages Anticipate GlycoMimetics Inc (GLYC) to Post -$0.28 EPS
www.americanbankingnews.com - April 11 at 11:16 PM
GlycoMimetics (GLYC) Stock Rating Upgraded by BidaskClubGlycoMimetics (GLYC) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - April 11 at 10:10 PM
GlycoMimetics (GLYC) & Adamis Pharmaceuticals (ADMP) Critical SurveyGlycoMimetics (GLYC) & Adamis Pharmaceuticals (ADMP) Critical Survey
www.americanbankingnews.com - April 5 at 9:50 AM
GlycoMimetics: Buy This DipGlycoMimetics: Buy This Dip
seekingalpha.com - April 4 at 3:48 PM
ValuEngine Upgrades GlycoMimetics (GLYC) to BuyValuEngine Upgrades GlycoMimetics (GLYC) to Buy
www.americanbankingnews.com - April 3 at 2:58 PM
GlycoMimetics (GLYC) Downgraded by Zacks Investment Research to HoldGlycoMimetics (GLYC) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - March 31 at 11:09 AM
New Research Coverage Highlights Healthcare Trust of America, Drive Shack, Chemed, AMERISAFE, Medical ...New Research Coverage Highlights Healthcare Trust of America, Drive Shack, Chemed, AMERISAFE, Medical ...
globenewswire.com - March 29 at 9:01 AM
GlycoMimetics Announces Pricing of Public Offering of Common StockGlycoMimetics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - March 28 at 9:02 AM
Zacks Investment Research Lowers GlycoMimetics (GLYC) to SellZacks Investment Research Lowers GlycoMimetics (GLYC) to Sell
www.americanbankingnews.com - March 27 at 11:28 PM
GlycoMimetics Inc (GLYC) Expected to Announce Earnings of -$0.28 Per ShareGlycoMimetics Inc (GLYC) Expected to Announce Earnings of -$0.28 Per Share
www.americanbankingnews.com - March 26 at 1:14 AM
GlycoMimetics Announces Pricing of Public Offering of Common Stock - Business Wire (press release)GlycoMimetics Announces Pricing of Public Offering of Common Stock - Business Wire (press release)
www.businesswire.com - March 21 at 9:41 AM
GlycoMimetics Announces Proposed Public Offering of Common StockGlycoMimetics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - March 19 at 4:52 PM
GlycoMimetics Inc (GLYC) Receives Consensus Rating of "Buy" from AnalystsGlycoMimetics Inc (GLYC) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - March 18 at 7:40 PM
GlycoMimetics (GLYC) and Regeneron Pharmaceuticals (REGN) Head to Head ContrastGlycoMimetics (GLYC) and Regeneron Pharmaceuticals (REGN) Head to Head Contrast
www.americanbankingnews.com - March 18 at 1:50 PM
GlycoMimetics to Present New Preclinical Data for GMI-1271 and GMI-1359 at AACR Annual Meeting 2018GlycoMimetics to Present New Preclinical Data for GMI-1271 and GMI-1359 at AACR Annual Meeting 2018
finance.yahoo.com - March 14 at 6:30 PM
GlycoMimetics (GLYC) Stock Rating Lowered by BidaskClubGlycoMimetics (GLYC) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - March 11 at 12:16 AM
Brokers Set Expectations for GlycoMimetics Incs Q1 2018 Earnings (GLYC)Brokers Set Expectations for GlycoMimetics Inc's Q1 2018 Earnings (GLYC)
www.americanbankingnews.com - March 9 at 7:54 AM
GlycoMimetics Inc to Post Q1 2018 Earnings of ($0.27) Per Share, Jefferies Group Forecasts (GLYC)GlycoMimetics Inc to Post Q1 2018 Earnings of ($0.27) Per Share, Jefferies Group Forecasts (GLYC)
www.americanbankingnews.com - March 9 at 7:54 AM
GlycoMimetics (GLYC) Downgraded to "Sell" at Zacks Investment ResearchGlycoMimetics (GLYC) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 8 at 11:04 PM
GlycoMimetics Inc (GLYC) to Post FY2022 Earnings of ($0.64) Per Share, SunTrust Banks ForecastsGlycoMimetics Inc (GLYC) to Post FY2022 Earnings of ($0.64) Per Share, SunTrust Banks Forecasts
www.americanbankingnews.com - March 8 at 2:58 PM
FY2018 Earnings Forecast for GlycoMimetics Inc Issued By Jefferies Group (GLYC)FY2018 Earnings Forecast for GlycoMimetics Inc Issued By Jefferies Group (GLYC)
www.americanbankingnews.com - March 8 at 9:08 AM
GlycoMimetics Reports Fourth Quarter and Year-End 2017 Results - Business Wire (press release)GlycoMimetics Reports Fourth Quarter and Year-End 2017 Results - Business Wire (press release)
www.businesswire.com - March 8 at 8:57 AM
Traders Buy Large Volume of GlycoMimetics Put Options (GLYC)Traders Buy Large Volume of GlycoMimetics Put Options (GLYC)
www.americanbankingnews.com - March 8 at 8:14 AM
GlycoMimetics Target of Unusually Large Options Trading (GLYC)GlycoMimetics Target of Unusually Large Options Trading (GLYC)
www.americanbankingnews.com - March 8 at 8:14 AM
GlycoMimetics (GLYC) PT Raised to $25.00 at Stifel NicolausGlycoMimetics (GLYC) PT Raised to $25.00 at Stifel Nicolaus
www.americanbankingnews.com - March 7 at 6:57 PM
GlycoMimetics to Present at Four Investor Conferences This MonthGlycoMimetics to Present at Four Investor Conferences This Month
finance.yahoo.com - March 7 at 5:57 PM
GlycoMimetics (GLYC) Releases  Earnings Results, Misses Expectations By $0.01 EPSGlycoMimetics (GLYC) Releases Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - March 7 at 11:50 AM
Why GlycoMimetics Is Tumbling 19.2% TodayWhy GlycoMimetics Is Tumbling 19.2% Today
finance.yahoo.com - March 6 at 5:18 PM
GlycoMimetics (GLYC) Announces Design of Phase 3 Clinical Trial for GMI-1271 in R/R AMLGlycoMimetics (GLYC) Announces Design of Phase 3 Clinical Trial for GMI-1271 in R/R AML
www.streetinsider.com - March 6 at 8:44 AM
GlycoMimetics Reports Fourth Quarter and Year-End 2017 ResultsGlycoMimetics Reports Fourth Quarter and Year-End 2017 Results
finance.yahoo.com - March 6 at 8:44 AM
When Can We Expect A Profit From GlycoMimetics Inc (NASDAQ:GLYC)?When Can We Expect A Profit From GlycoMimetics Inc (NASDAQ:GLYC)?
finance.yahoo.com - March 5 at 5:30 PM
Should You Buy GlycoMimetics (GLYC) Ahead of Earnings?Should You Buy GlycoMimetics (GLYC) Ahead of Earnings?
www.zacks.com - March 5 at 8:48 AM

SEC Filings

GlycoMimetics (NASDAQ:GLYC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

GlycoMimetics (NASDAQ:GLYC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

GlycoMimetics (NASDAQ GLYC) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.